Focus: Vera Therapeutics is a public biotech company specializing in gene editing technology and gene therapy, with a focus on immunology and oncology indications. The company operates at mid-cap scale with 51-200 employees and is headquartered in Brisbane, CA.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
Vera offers mid-cap biotech career stability with Phase 3 catalysts and commercial hiring, but persistent losses and opaque pipeline quality warrant due diligence on financial runway and program credibility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Vera Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vera Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Vera Therapeutics, Inc. Stock 12‑Month Price Target Cut to $77.07, Implies 159% Upside - TradingView
Vera Therapeutics, Inc. Stock 12‑Month Price Target Cut to $77.07, Implies 159% Upside TradingView
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) The Manila Times
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 - The Manila Times
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 The Manila Times
Five new hires at Vera Therapeutics received share options and awards that vest over four years. - Stock Titan
Five new hires at Vera Therapeutics received share options and awards that vest over four years. Stock Titan
Vera Therapeutics Announces ORIGIN 3 Final Efficacy - GlobeNewswire
Vera Therapeutics Announces ORIGIN 3 Final Efficacy GlobeNewswire
Vera Therapeutics (NASDAQ: VERA) CEO exercises options and sells shares under preset trading plan - Stock Titan
Vera Therapeutics (NASDAQ: VERA) CEO exercises options and sells shares under preset trading plan Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 8 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo